Professor Benjamin A Weinberg (Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA) summarises key data from pivotal studies in colorectal cancer that were presented at the ASCO Gastrointestinal Cancers Symposium 2022.
- GALAXY study in CIRCULATE-Japan abstract: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.009
Clinical trial information: jRCT1031200006
- RESPECT study abstract: https://meetings.asco.org/abstracts-presentations/204531
Clinical Trial Registration Number: UMIN000008866
- GERCOR NIPICOL study abstract: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.013
Clinical trial information: NCT033501260.
- What has the GALAXY study taught us about ctDNA dynamics and clinical outcomes in the management of patients with resectable colorectal cancer (CRC)? (00:15-01:45)
- Following the RESPECT study, what should be the preferred first-line treatment for patients with metastatic (m)CRC aged 75+? (01:45-03:30)
- According to the latest GERCOR NIPICOL data, when is the best time to stop immunotherapy in patients with microsatellite instability-high/mismatch repair deficient mCRC? (03:30-05:01)
- What have we learned about the use of neoadjuvant dostarlimab for MSI-H locally advanced CRC? (05:01-06:10)
- What is the potential of BEACON plus nivolumab for BRAF V600E mutated mCRC? (06:10-07:52)
Speaker Disclosure: Benjamin A Weinberg has no conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ASCO Gastrointestinal Cancers Symposium 2022.
Share this Video
Related Videos In Gastrointestinal Oncology
Benjamin Weingberg, ASCO 2022: Highlights of ASCO in colorectal cancer, dostarlimab and the DYNAMIC study
Professor Benjamin Weinberg (Georgetown University, Washington, DC, USA) discusses the highlights of colorectal cancer at ASCO 2022. A subset of colorectal cancer is mismatch repair deficient and is responsive to PD-1 blockade in the metastatic setting. This led to the phase II study where dostarlimab, an anti PD-1 monoclonal antibody, was administered to patients with […]
Benjamin Weingberg, ASCO 2022: Highlights of ASCO in colorectal cancer, the PARADIGM study
PARADIGM is the first prospective trial to examine panitumumab versus bevacizumab in colorectal cancer. Professor Benjamin Weinberg (Georgetown University, Washington, DC, USA) discusses the findings of the phase III PARADIGM study in patients with RAS wild-type (WT) metastatic colorectal cancer. The abstract entitled ‘Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment […]
Takayuki Yoshino, ASCO 2022: PARADIGM trial of panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with MCRC
Dr Takayuki Yoshino (National Cancer Center Hospital East, Chiba, Japan) discusses the findings from the phase 3 PARADIGM trial, which was part of a plenary session and selected as one of the top abstracts from the conference. The trial assessed panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with RAS wild-type […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!